- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07717619
Antenatal High-Risk Pregnancy Intervention Bundle in Rural Nepal
15 juli 2026 bijgewerkt door: University of California, San Francisco
Implementing and Evaluating an Antenatal High-Risk Pregnancy Intervention Bundle in Rural Nepal
The proposed study will assess and implement a comprehensive antenatal HRP screening and telehealth follow-up program in rural Nepal. The main questions it aims to answer are:
- To estimate the burden of HRPs using the existing Antenatal Risk-Score Checklist in rural Nepal
- Assess acceptability, feasibility, preliminary effectiveness, and implementation outcomes of the HRP bundle at the primary healthcare in Nepal
Studie Overzicht
Toestand
Nog niet aan het werven
Conditie
Interventie / Behandeling
Studietype
Ingrijpend
Inschrijving (Geschat)
100
Fase
- Niet toepasbaar
Contacten en locaties
In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.
Studiecontact
- Naam: Archana Shrestha, PhD
- Telefoonnummer: +9779801002245
- E-mail: archana@kusms.edu.np
Studie Contact Back-up
- Naam: Anju Ranjit, MD MPH
- Telefoonnummer: 4153533400
- E-mail: anju.ranjit@ucsf.edu
Studie Locaties
-
-
Bagmati
-
Melamchi, Bagmati, Nepal
- Melamchi Primary Health Care Center
-
Contact:
- Umang Raut (Medical Superintendent)
- Telefoonnummer: +977 9860923221
- E-mail: melamchiphc@gmail.com
-
-
Deelname Criteria
Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
- Kind
- Volwassen
- Oudere volwassene
Accepteert gezonde vrijwilligers
Ja
Beschrijving
Inclusion Criteria:
- all pregnant women above who are receiving antenatal care at Melamchi Primary Health Care Center
Exclusion Criteria:
- life-threatening maternal or fetal conditions requiring immediate tertiary-level care
- unable to provide informed consent due to cognitive or language barriers
- do not have access to a mobile phone for telehealth consultations.
Studie plan
Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Onderzoek naar gezondheidsdiensten
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Geen tussenkomst: Standard of Care
Usual prenatal care, including on-site consultation and visits from health facility staff
|
|
|
Actieve vergelijker: High Risk Pregnancy (HRP) Bundle Intervention Arm
The intervention arm would include 1. identification of high-risk pregnancy 2. Teleconsultation with expert consultant 3. weekly call with patient navigator 4. training of health care provider for HRP care, and 5. visits in the weekly prenatal telehealth clinic
|
The intervention would include 1. identification of high-risk pregnancy 2. Teleconsultation with expert consultant 3. weekly call with patient navigator 4. training of health care provider for HRP care, and 5. visits in the weekly prenatal telehealth clinic
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Maternal Near Miss
Tijdsspanne: up to 60 days postpartum
|
life-threatening complication during pregnancy, childbirth, or within 42 days postpartum, but survives with appropriate medical intervention (We will use WHO criteria)
|
up to 60 days postpartum
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Neonatal death
Tijdsspanne: Up to 28 days after birth
|
Number of neonatal deaths, defined as death of a liveborn infant within the first 28 days of life
|
Up to 28 days after birth
|
|
Low Apgar Score at 5 Minutes
Tijdsspanne: At 5 minutes after birth
|
Number of infants with an Apgar score less than 7 at 5 minutes after birth
|
At 5 minutes after birth
|
|
Neonatal Intensive Care Unit Admission
Tijdsspanne: Up to 30 days after birth
|
Number of infants admitted to a neonatal intensive care unit
|
Up to 30 days after birth
|
|
Need for Mechanical Ventilation
Tijdsspanne: up to 30 days after birth
|
Number of infants requiring mechanical ventilation
|
up to 30 days after birth
|
|
Neonatal Respiratory Distress Syndrome
Tijdsspanne: Up to 30 days after birth
|
Number of infants diagnosed with respiratory distress syndrome
|
Up to 30 days after birth
|
|
Neonatal Hypoglycemia
Tijdsspanne: Up to 48 hours after birth
|
Number of infants with hypoglycemia, defined as less than 45 mg/dl
|
Up to 48 hours after birth
|
|
Low Birth Weight
Tijdsspanne: At birth
|
Number of infants with birth weight less than 2500 grams
|
At birth
|
|
Composite Adverse Neonatal Outcome
Tijdsspanne: up to 30 days after birth
|
Number of infants with at least one of the following: neonatal death, Apgar score less than 7 at 5 minutes, NICU admission, need for mechanical ventilation, respiratory distress syndrome, hypoglycemia
|
up to 30 days after birth
|
|
Antenatal Risk Screening Rate
Tijdsspanne: Up to 24 months
|
Proportion of pregnant women enrolled in the study who undergo antenatal risk screening using the Antenatal Risk-Score Checklist
|
Up to 24 months
|
|
Referral Rate
Tijdsspanne: Up to 24 months
|
Percentage of pregnant women referred to higher levels of care based on risks identified through antenatal risk screening
|
Up to 24 months
|
|
Telehealth Consultation Utilization Rate
Tijdsspanne: Up to 24 months
|
Proportion of pregnant women in the High Risk Pregnancy Bundle Intervention Arm who utilize at least 80% of their recommended telehealth consultations
|
Up to 24 months
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Acceptability of Intervention Measure (AIM) Score
Tijdsspanne: up to 24 months
|
We will assess the acceptability of each intervention component (risk-screening scoring system, teleconsultation, weekly patient navigator calls, and provider training) using the mean total score and standard deviation (SD) of the Acceptability of Intervention Measure (AIM), administered at both the patient and provider level.
|
up to 24 months
|
|
Intervention Appropriateness Measure (IAM) Score
Tijdsspanne: Up to 24 months
|
We will assess the appropriateness of each intervention component (risk-screening scoring system, teleconsultation, weekly patient navigator calls, and provider training) using the mean total score and standard deviation (SD) of the Intervention Appropriateness Measure (IAM), administered at both the patient and provider level.
|
Up to 24 months
|
|
Feasibility of Intervention Measure (FIM) Score
Tijdsspanne: Up to 24 months
|
We will assess the feasibility of each intervention component (risk-screening scoring system, teleconsultation, weekly patient navigator calls, and provider training) using the mean total score and standard deviation (SD) of the Feasibility of Intervention Measure (FIM), administered at both the patient and provider level.
|
Up to 24 months
|
Medewerkers en onderzoekers
Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.
Onderzoekers
- Hoofdonderzoeker: Anju Ranjit, MD MPH, University of California, San Francisco
- Hoofdonderzoeker: Archana Shrestha, Kathmandu University School of Medicine/Dhulikhel Hospital
Studie record data
Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.
Bestudeer belangrijke data
Studie start (Geschat)
1 augustus 2026
Primaire voltooiing (Geschat)
31 juli 2027
Studie voltooiing (Geschat)
31 juli 2028
Studieregistratiedata
Eerst ingediend
25 juni 2026
Eerst ingediend dat voldeed aan de QC-criteria
15 juli 2026
Eerst geplaatst (Werkelijk)
21 juli 2026
Updates van studierecords
Laatste update geplaatst (Werkelijk)
21 juli 2026
Laatste update ingediend die voldeed aan QC-criteria
15 juli 2026
Laatst geverifieerd
1 juli 2026
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- 26-46873
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
JA
Beschrijving IPD-plan
De-identified individual participant data will be shared, including quantitative survey data on primary outcomes (maternal near-miss) and secondary outcomes (maternal mortality, composite neonatal outcomes, stillbirth rate, preterm delivery, implementation outcomes), socio-demographic and reproductive health data, and chronic health condition data.
Qualitative data (de-identified transcripts) from focus group discussions and in-depth interviews on implementation barriers and facilitators will also be shared.
Process tracking data (service utilization records, monthly reports) may be shared in aggregate form.
Personally identifiable information will be removed prior to sharing.
Data will be shared in standard formats (e.g., Stata) in accordance with ICPSR standards, accompanied by a codebook and questionnaire to support interpretation.
IPD-tijdsbestek voor delen
Individual participant data and supporting information will be available beginning at the time of publication of the associated study results.
Data will remain available indefinitely upon request following publication, with no specified end date.
IPD-toegangscriteria voor delen
De-identified data will be accessible to qualified researchers and program implementers who submit a formal data request and agree to comply with applicable ethical guidelines and data use terms.
Requestors will have access to de-identified quantitative datasets, qualitative transcripts, and associated metadata (questionnaire, codebook).
Potentially identifying variables will be classified under restricted access and made available only through a secure virtual data enclave (e.g., DSDR/ICPSR) for approved researchers.
Data will be archived on a secure server at Dhulikhel Hospital-Kathmandu University Hospital, with a backup at UCSF.
Requests will be reviewed by the study's Principal Investigators or designated project coordinator.
A Certificate of Confidentiality will safeguard participant information throughout the access process.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Nee
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Nee
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .